Phase I Trial of Sorafenib and Gemcitabine in Advanced Solid Tumors with an Expanded Cohort in Advanced Pancreatic Cancer
Abstract Background: With its potent inhibitory effects against Raf-1 kinase and vascular endothelial growth factor receptor-2, sorafenib is a novel oral anticancer agent targeting signal transduction and angiogenic pathways. This study is designed to combine sorafenib and gemcitabine due to their c...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | engelsk |
| Udgivet: |
2006
|
| Online adgang: | https://doi.org/10.1158/1078-0432.ccr-05-1571 https://aacrjournals.org/clincancerres/article-pdf/12/1/144/1962003/144.pdf |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|